These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28858508)

  • 1. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.
    Xu GG; Pagare PP; Ghatge MS; Safo RP; Gazi A; Chen Q; David T; Alabbas AB; Musayev FN; Venitz J; Zhang Y; Safo MK; Abdulmalik O
    Mol Pharm; 2017 Oct; 14(10):3499-3511. PubMed ID: 28858508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease.
    Pagare PP; Ghatge MS; Musayev FN; Deshpande TM; Chen Q; Braxton C; Kim S; Venitz J; Zhang Y; Abdulmalik O; Safo MK
    Bioorg Med Chem; 2018 May; 26(9):2530-2538. PubMed ID: 29655608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.
    Safo MK; Kato GJ
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):217-31. PubMed ID: 24589263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds.
    Safo MK; Abdulmalik O; Danso-Danquah R; Burnett JC; Nokuri S; Joshi GS; Musayev FN; Asakura T; Abraham DJ
    J Med Chem; 2004 Sep; 47(19):4665-76. PubMed ID: 15341482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antisickling agent, 5-hydroxymethyl-2-furfural: Other potential pharmacological applications.
    Pagare PP; McGinn M; Ghatge MS; Shekhar V; Alhashimi RT; Daniel Pierce B; Abdulmalik O; Zhang Y; Safo MK
    Med Res Rev; 2024 Nov; 44(6):2707-2729. PubMed ID: 38842004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation.
    Deshpande TM; Pagare PP; Ghatge MS; Chen Q; Musayev FN; Venitz J; Zhang Y; Abdulmalik O; Safo MK
    Acta Crystallogr D Struct Biol; 2018 Oct; 74(Pt 10):956-964. PubMed ID: 30289405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions.
    Abdulmalik O; Pagare PP; Huang B; Xu GG; Ghatge MS; Xu X; Chen Q; Anabaraonye N; Musayev FN; Omar AM; Venitz J; Zhang Y; Safo MK
    Sci Rep; 2020 Nov; 10(1):20277. PubMed ID: 33219275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells.
    Abdulmalik O; Safo MK; Chen Q; Yang J; Brugnara C; Ohene-Frempong K; Abraham DJ; Asakura T
    Br J Haematol; 2005 Feb; 128(4):552-61. PubMed ID: 15686467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted modification of furan-2-carboxaldehydes into Michael acceptor analogs yielded long-acting hemoglobin modulators with dual antisickling activities.
    Omar AM; Abdulmalik O; El-Say KM; Ghatge MS; Cyril-Olutayo M; Paredes S; Al-Awadh M; El-Araby ME; Safo MK
    Chem Biol Drug Des; 2024 Jan; 103(1):e14371. PubMed ID: 37798397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
    Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI
    Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells.
    Nakagawa A; Ferrari M; Schleifer G; Cooper MK; Liu C; Yu B; Berra L; Klings ES; Safo RS; Chen Q; Musayev FN; Safo MK; Abdulmalik O; Bloch DB; Zapol WM
    Mol Pharm; 2018 May; 15(5):1954-1963. PubMed ID: 29634905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.
    Omar AM; Abdulmalik O; Ghatge MS; Muhammad YA; Paredes SD; El-Araby ME; Safo MK
    Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33147875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin.
    Abdulmalik O; Ghatge MS; Musayev FN; Parikh A; Chen Q; Yang J; Nnamani I; Danso-Danquah R; Eseonu DN; Asakura T; Abraham DJ; Venitz J; Safo MK
    Acta Crystallogr D Biol Crystallogr; 2011 Nov; 67(Pt 11):920-8. PubMed ID: 22101818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent.
    Iyamu EW; Turner EA; Asakura T
    Br J Haematol; 2002 Jul; 118(1):337-43. PubMed ID: 12100171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, and Evaluation of Allosteric Effectors for Hemoglobin.
    Enakaya NA; Jefferson A; Chew-Martinez D; Matthews JS
    Acc Chem Res; 2023 Jun; 56(11):1279-1286. PubMed ID: 36946781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
    Oder E; Safo MK; Abdulmalik O; Kato GJ
    Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
    Henry ER; Metaferia B; Li Q; Harper J; Best RB; Glass KE; Cellmer T; Dunkelberger EB; Conrey A; Thein SL; Bunn HF; Eaton WA
    Blood; 2021 Sep; 138(13):1172-1181. PubMed ID: 34197597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin.
    Omar AM; Mahran MA; Ghatge MS; Bamane FH; Ahmed MH; El-Araby ME; Abdulmalik O; Safo MK
    Molecules; 2016 Aug; 21(8):. PubMed ID: 27529207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
    Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
    Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease.
    Li Q; Henry ER; Hofrichter J; Smith JF; Cellmer T; Dunkelberger EB; Metaferia BB; Jones-Straehle S; Boutom S; Christoph GW; Wakefield TH; Link ME; Staton D; Vass ER; Miller JL; Hsieh MM; Tisdale JF; Eaton WA
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):E689-E696. PubMed ID: 28096387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.